A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

BACKGROUND: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Avallone, Antonio, Piccirillo, Maria Carmela, Aloj, Luigi, Nasti, Guglielmo, Delrio, Paolo, Izzo, Francesco, Di Gennaro, Elena, Tatangelo, Fabiana, Granata, Vincenza, Cavalcanti, Ernesta, Maiolino, Piera, Bianco, Francesco, Aprea, Pasquale, De Bellis, Mario, Pecori, Biagio, Rosati, Gerardo, Carlomagno, Chiara, Bertolini, Alessandro, Gallo, Ciro, Romano, Carmela, Leone, Alessandra, Caracò, Corradina, de Lutio di Castelguidone, Elisabetta, Daniele, Gennaro, Catalano, Orlando, Botti, Gerardo, Petrillo, Antonella, Romano, Giovanni M., Iaffaioli, Vincenzo R., Lastoria, Secondo, Perrone, Francesco, Budillon, Alfredo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Study Protocol
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746902/
https://ncbi.nlm.nih.gov/pubmed/26857924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2102-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak